Key Highlights
- Contineum Therapeutics' Johnson & Johnson-partnered asset, JNJ-5120/PIPE-307, missed its primary endpoint in the Phase 2 MOONLIGHT-1 study.
- The study targeted major depressive disorder.
- The compound failed to show a statistically significant MADRS total score reduction against placebo at Day 5.
- The compound was well tolerated, with zero novel safety concerns.
Contineum Therapeutics, Inc. (NASDAQ: CTNM) reported that its Johnson & Johnson-partnered asset, JNJ-5120/PIPE-307, missed its primary endpoint within the Phase 2 MOONLIGHT-1 major depressive disorder study, failing to show a statistically significant MADRS total score reduction against placebo at Day 5.
What Happened
Though the compound was well tolerated with zero novel safety concerns, exploratory evaluation continues to guide future development.
Market Reaction
The disclosed information does not include stock price or trading data for Contineum Therapeutics following the MOONLIGHT-1 results.
Outlook
Continued exploratory evaluation of JNJ-5120/PIPE-307 following the MOONLIGHT-1 miss represents the next relevant step in guiding the program's future development path.
FAQs
Q: What did the Phase 2 MOONLIGHT-1 study test?
A: JNJ-5120/PIPE-307, a Johnson & Johnson-partnered asset, in major depressive disorder.
Q: Did the study meet its primary endpoint?
A: No, it failed to show a statistically significant MADRS total score reduction against placebo at Day 5.
Q: Were there safety concerns with the compound?
A: No, the compound was well tolerated with zero novel safety concerns.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.